drugset
drugset / Trial / NCT00952913

Study Evaluating The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib In Healthy Subjects

NCT00952913 ↗

Phase 1 Completed 24 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if there is an effect on the pharmacokinetics of bosutinib when administered with lansoprazole.

Timeline

Start
2009-08
Primary completion
2009-10
Completion
2009-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosutinib Small molecule 400 mg Oral
Subject Lansoprazole Other / unclassified 60 mg Oral

Indications

No indication recorded.